Grant: Operating Grant
University of British Columbia
$248,442.00
The role of serum lipoproteins in optimizing amphotericin B therapy
EF 2009-10
Résumé
Previous studies in the Wasan lab have shown that when drugs associate with plasma lipids (i.e. HDL and LDL) they result
in a change in the drug's activity and toxicity. In the case of amphotericin B, an antifungal agent, we have animal and human data that suggests that when the drug is associated with LDL, it is kidney toxic limiting its use. This project will determine if changes in the patient's plasma lipid levels result in altered amphotericin B induced kidney toxicity. Outcomes from this study will help physicians improve drug efficacy and patient quality of life as well as save health care costs.
Programme
Operating Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
198260
Name
Wasan Kishor M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
The role of serum lipoproteins in optimizing amphotericin B therapy
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$248,442
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Amphotericin B; Amphotericin B Lipid Complex; Cholesteryl Ester Transfer Protein; Hplc; Infectious Diseases And Co-Infection Issues; Lipoproteins
Abstract
Previous studies in the Wasan lab have shown that when drugs associate with plasma lipids (i.e. HDL and LDL) they result
in a change in the drug's activity and toxicity. In the case of amphotericin B, an antifungal agent, we have animal and human data that suggests that when the drug is associated with LDL, it is kidney toxic limiting its use. This project will determine if changes in the patient's plasma lipid levels result in altered amphotericin B induced kidney toxicity. Outcomes from this study will help physicians improve drug efficacy and patient quality of life as well as save health care costs.
Competitiondate
201003
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wasan, Kishor M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $248,442~ $0~
